U.S., July 26 -- ClinicalTrials.gov registry received information related to the study (NCT07085091) titled 'A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors' on June 27.
Brief Summary: A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
NSCLC (Advanced Non-small Cell Lung Cancer)
HNSCC
CRC (Colorectal Cancer)
ESCC
Colo-rectal Cancer
Head and Neck Cancer
Esophageal Squamous Cell Carcinoma (ESCC)
Intervention:
DRUG: ALX2004
ALX2004 is a novel ADC targeting EGFR. Drug: ALX2004 IV Infusion
DRUG: ALX2004
A...